IRCT20200205046378N1尚未招募未知
arthroscopic lateral patella retinaculum releasing through/outside synovial membrane for the treatment of lateral patellar compression syndrome
ational Natural Science Foundation of China0 个研究点目标入组 125 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 125
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 16 years 至 66 years（—）
- 性别
- All
入选标准
- •The symptoms of anterior knee pain in the unilateral knee joint were not significantly relieved after 3-6 months of standardized non-surgical treatment;
- •Preoperative examination showed that the LPR was tightened;
- •Imaging examination prompted the patella tilt to the outside and Q angle was normal.
排除标准
- •Patients had the history of dislocation or subluxation of patella or excessive Q angle (>20°);
- •Severe patellofemoral arthritis was not suitable for LPRR alone;
- •Other diseases were not suitable for surgery treatment.
研究者
相似试验
已完成
Unknown
Arthroscopic assisted release of lateral pterygoid versus scarification of retrodiscal tissue in management of internal derangement of temporomandibular joint: RCTPACTR202303632334777Oral and Maxillofacial Surgery Department Faculty of Dentistry Tanta University16
进行中（未招募）
1 期
TENECTEPLASE IN CENTRAL RETINAL ARTERY OCCLUSION STUDY(TenCRAOS): A RANDOMIZED CONTROLLED TRIAL OF ACUTE CLOTSOLVING MEDICATION IN CENTRAL RETINALY ARTERY OCCLUSION.Central retinal artery occlusionEUCTR2018-002546-36-NOOslo University Hospital78
进行中（未招募）
1 期
TENECTEPLASE IN CENTRAL RETINAL ARTERY OCCLUSION STUDY(TenCRAOS): A RANDOMIZED CONTROLLED TRIAL OF ACUTE CLOTSOLVING MEDICATION IN CENTRAL RETINALY ARTERY OCCLUSION.Central retinal artery occlusionEUCTR2018-002546-36-LTOslo University Hospital78
进行中（未招募）
1 期
TENECTEPLASE IN CENTRAL RETINAL ARTERY OCCLUSION STUDY(TenCRAOS): A RANDOMIZED CONTROLLED TRIAL OF ACUTE CLOTSOLVING MEDICATION IN CENTRAL RETINALY ARTERY OCCLUSION.Central retinal artery occlusionEUCTR2018-002546-36-FIOslo University Hospital78
招募中
3 期
TENECTEPLASE IN CENTRAL RETINAL ARTERY OCCLUSION STUDY
(TenCRAOS):
A Prospective, randomised-controlled, double-dummy, double-blind phase 3 multi-centre trial of
TNK 0.25 mg/kg + placebo vs. ASA + placebo (2 arms with 1:1 block randomisation)Central retinal artery occlusion2024-517606-29-00Oslo University Hospital HF76